menu
    • menu
    [{"orgOrder":0,"company":"Oncologie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bavituximab","moa":"||Phosphatidylserine","graph1":"Oncology","graph2":"Phase II","graph3":"Oncologie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncologie \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncologie \/ Inapplicable"},{"orgOrder":0,"company":"Oncologie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bavituximab","moa":"||Phosphatidylserine","graph1":"Oncology","graph2":"Phase II","graph3":"Oncologie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncologie \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncologie \/ Inapplicable"},{"orgOrder":0,"company":"Oncologie","sponsor":"Mereo BioPharma Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Navicixizumab","moa":"monoclonal antibodies: combination of humanized and chimeric chains","graph1":"Oncology","graph2":"Phase I","graph3":"Oncologie","amount2":0.31,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.31,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncologie \/ Oncologie","highestDevelopmentStatusID":"6","companyTruncated":"Oncologie \/ Oncologie"}]

    Find Clinical Drug Pipeline Developments & Deals by Oncologie

    Menu

    Oncologie

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Oncologie

                            U.S.A arrow
                            CAMX
                            Not Confirmed

                            Oncologie

                            U.S.A arrow
                            CAMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bavituximab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oncologie Announces New Data and Analyses from Clinical Programs and Name Change to OncXerna Therapeutics

                            Details : Interim results from a Phase 2 trial of bavituximab with KEYTRUDA® (pembrolizumab) demonstrates a 19% overall response rate (ORR) and 43% (3/7) ORR from an exploratory analysis in a biomarker-driven subgroup of advanced gastric cancer patients.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            September 18, 2020

                            Lead Product(s) : Bavituximab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Oncologie

                            U.S.A arrow
                            CAMX
                            Not Confirmed

                            Oncologie

                            U.S.A arrow
                            CAMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bavituximab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oncologie Announces Key Updates and Planned Activities for its Clinical Programs and RNA-based Biomarker Platf...

                            Details : Oncologie is conducting Phase 2 trial to further evaluate the safety, tolerability, and antitumor activity of bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal junction cancer.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            June 16, 2020

                            Lead Product(s) : Bavituximab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Oncologie

                            U.S.A arrow
                            CAMX
                            Not Confirmed

                            Oncologie

                            U.S.A arrow
                            CAMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Navicixizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Mereo BioPharma Group

                            Deal Size : $306.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab

                            Details : Under the terms and conditions of the agreement, Oncologie receives exclusive global license to develop and commercialize navicixizumab.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : $4.0 million

                            January 13, 2020

                            Lead Product(s) : Navicixizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Mereo BioPharma Group

                            Deal Size : $306.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth